SCHEMBL474836

SCHEMBL474836

NNC(=O)c1c[nH]c2ccccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.66
ATM Q13315 1/20 0.66
GPR84 Q9NQS5 1/20 0.65
PBRM1 Q86U86 1/20 0.61
NR4A2 P43354 1/20 0.60
CREBBP Q92793 1/20 0.60
NPC1 O15118 3/20 0.59
ADAM17 P78536 1/20 0.57
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
TUBB4A P04350 1/20 0.56
TUBB P07437 1/20 0.56
TUBA3C P0DPH7 1/20 0.56
TUBA1B P68363 1/20 0.56
TUBA4A P68366 1/20 0.56
TUBB4B P68371 1/20 0.56
TUBB3 Q13509 1/20 0.56
TUBB2A Q13885 1/20 0.56
TUBB8 Q3ZCM7 1/20 0.56
TUBA3E Q6PEY2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL31312793 0.98 ALDH1A1 (0.64) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL24254359 0.88 CFTR (0.68) ALDH1A1ATMGABRA1GABRB2
SCHEMBL31411210 0.84 GPR84 (0.67) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL3122183 0.83 ALDH1A1 (0.67) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL5768987 0.82 PBRM1 (0.66) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL28460337 0.81 NR4A2 (0.69) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL12903051 0.81 PBRM1 (0.60) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL7399821 0.81 NR4A2 (0.63) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL7456891 0.81 PBRM1 (0.69) ALDH1A1ATMGPR84PBRM1NR4A2
SCHEMBL8251765 0.80 GABRP (0.74) NPC1RAB9AGABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036615-A Indazole hydrazide compound and preparation method and application thereof 南京农业大学 2026-05-15 CN claimed
CN-118812539-A 5-Aminotriazolopyrimidine derivative and preparation method thereof 苏州大学 2024-10-22 CN claimed
CN-113087651-B Compound containing indole group and preparation method and application thereof 华南师范大学 2023-03-10 CN claimed
CN-115160209-A Indole group-containing compound and preparation method and application thereof 华南师范大学 2022-10-11 CN claimed
CN-111349088-B Indole-based heterocyclic compounds, preparation method thereof and application thereof in controlling plant diseases 天津师范大学 2022-09-20 CN claimed
CN-111349080-B Indole acylhydrazone compound, preparation method thereof and application of indole acylhydrazone compound in prevention and treatment of plant diseases 天津师范大学 2022-08-26 CN claimed
CN-113562855-A Environment-friendly efficient boiler water regulator for drum boiler 浙江砉润科技有限公司 2021-10-29 CN claimed
CN-113087651-A Compound containing indole group and preparation method and application thereof 华南师范大学 2021-07-09 CN claimed
CN-111689973-A Dibenzocaprolactam pyrazolidine compound, preparation method and application 朱翠萍 2020-09-22 CN claimed
CN-111349038-A Indolylhydrazone compounds, preparation method thereof and application thereof in preventing and treating plant diseases 天津师范大学 2020-06-30 CN claimed
US-20030119860-A1 METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS ELI LILLY AND COMPANY 2003-06-26 US claimed
US-20030087944-A1 Method for the treatment of renal dysfunction with spla2 inhibitors CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) 2003-05-08 US claimed
EP-1265607-A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001066111-A1 COMPOSITIONS CONTAINING POTENTIAL SPLA2 INHIBITORS FOR THE TREATMENT OF PAIN ELI LILLY AND COMPANY (US) 2001-09-13 WO claimed
WO-2001066110-A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2001-09-13 WO claimed
WO-2001055108-A2 USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION ELI LILLY AND COMPANY (US) 2001-08-02 WO claimed
EP-1011670-A1 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS ELI LILLY AND COMPANY (US) 2000-06-28 EP claimed
EP-1007056-A1 METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS ELI LILLY AND COMPANY (US) 2000-06-14 EP claimed
WO-1999016453-A1 METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS ELI LILLY AND COMPANY (US) 1999-04-08 WO claimed
WO-1999009978-A1 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS ELI LILLY AND COMPANY (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087944-A1 Method for the treatment of renal dysfunction with spla2 inhibitors IDO2, SPINT2, IDO1 ALDH1A1 2210/4885ATM 4294/4885GPR84 1411/4885
US-20030119860-A1 METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS TPP2, PLAAT2, PLAA ALDH1A1 1230/4885ATM 4767/4885GPR84 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.